FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750541839> ?p ?o ?g. }

• W2750541839 endingPage "15" @default.
• W2750541839 startingPage "1" @default.
• W2750541839 abstract "Patients with breast tumors that do not express the estrogen receptor, the progesterone receptor, nor Her-2/neu are hence termed triple negatives, and generally have a poor prognosis, with high rates of systemic recurrence and refractoriness to conventional therapy regardless of the choice of adjuvant treatment. Thus, more effective therapeutic options are sorely needed for triple-negative breast cancer (TNBC), which occurs in approximately 20% of diagnosed breast cancers. In recent years, exploiting intrinsic mechanisms of the host immune system to eradicate cancer cells has achieved impressive success, and the advances in immunotherapy have yielded potential new therapeutic strategies for the treatment of this devastating subtype of breast cancer. It is anticipated that the responses initiated by immunotherapeutic interventions will explicitly target and annihilate tumor cells, while at the same time spare normal cells. Various immunotherapeutic approaches have been already developed and tested, which include the blockade of immune checkpoints using neutralizing or blocking antibodies, induction of cytotoxic T lymphocytes (CTLs), adoptive cell transfer-based therapy, and modulation of the tumor microenvironment to enhance the activity of CTLs. One of the most important areas of breast cancer research today is understanding the immune features and profiles of TNBC and devising novel immune-modulatory strategies to tackling TNBC, a subtype of breast cancer notorious for its poor prognosis and its imperviousness to conventional treatments. On the optimal side, one can anticipate that novel, effective, and personalized immunotherapy for TNBC will soon achieve more success and impact clinical treatment of this disease which afflicts approximately 20% of patients with breast cancer. In the present review, we highlight the current progress and encouraging developments in cancer immunotherapy, with a goal to discuss the challenges and to provide future perspectives on how to exploit a variety of new immunotherapeutic approaches including checkpoint inhibitors and neoadjuvant immunotherapy for the treatment of patients with TNBC." @default.
• W2750541839 created "2017-08-31" @default.
• W2750541839 creator A5028143969 @default.
• W2750541839 creator A5044956525 @default.
• W2750541839 creator A5045415662 @default.
• W2750541839 creator A5046643126 @default.
• W2750541839 creator A5052750238 @default.
• W2750541839 creator A5057409749 @default.
• W2750541839 creator A5078674610 @default.
• W2750541839 creator A5088953254 @default.
• W2750541839 date "2017-05-01" @default.
• W2750541839 modified "2023-09-29" @default.
• W2750541839 title "Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects" @default.
• W2750541839 cites W1132077651 @default.
• W2750541839 cites W1159969767 @default.
• W2750541839 cites W1510442926 @default.
• W2750541839 cites W1568317937 @default.
• W2750541839 cites W1587494635 @default.
• W2750541839 cites W1647475986 @default.
• W2750541839 cites W1702502468 @default.
• W2750541839 cites W1781719481 @default.
• W2750541839 cites W1841979777 @default.
• W2750541839 cites W1963987641 @default.
• W2750541839 cites W1966023886 @default.
• W2750541839 cites W1967329857 @default.
• W2750541839 cites W1975079155 @default.
• W2750541839 cites W1976632546 @default.
• W2750541839 cites W1978459311 @default.
• W2750541839 cites W1979936799 @default.
• W2750541839 cites W1981725818 @default.
• W2750541839 cites W1982488143 @default.
• W2750541839 cites W1984545852 @default.
• W2750541839 cites W1985770829 @default.
• W2750541839 cites W1985981664 @default.
• W2750541839 cites W1986989859 @default.
• W2750541839 cites W1994420568 @default.
• W2750541839 cites W1994826332 @default.
• W2750541839 cites W1995224853 @default.
• W2750541839 cites W1996188527 @default.
• W2750541839 cites W2002952328 @default.
• W2750541839 cites W2015544847 @default.
• W2750541839 cites W2017712207 @default.
• W2750541839 cites W2019633596 @default.
• W2750541839 cites W2021165507 @default.
• W2750541839 cites W2023753181 @default.
• W2750541839 cites W2023980114 @default.
• W2750541839 cites W2032166347 @default.
• W2750541839 cites W2035967822 @default.
• W2750541839 cites W2041143310 @default.
• W2750541839 cites W2047902191 @default.
• W2750541839 cites W2052855154 @default.
• W2750541839 cites W2057574963 @default.
• W2750541839 cites W2060629187 @default.
• W2750541839 cites W2060878129 @default.
• W2750541839 cites W2063264144 @default.
• W2750541839 cites W2063813632 @default.
• W2750541839 cites W2064688742 @default.
• W2750541839 cites W2065543285 @default.
• W2750541839 cites W2070631889 @default.
• W2750541839 cites W2072629032 @default.
• W2750541839 cites W2074546881 @default.
• W2750541839 cites W2075894019 @default.
• W2750541839 cites W2076777479 @default.
• W2750541839 cites W2079315541 @default.
• W2750541839 cites W2082326948 @default.
• W2750541839 cites W2082830752 @default.
• W2750541839 cites W2087482409 @default.
• W2750541839 cites W2096027508 @default.
• W2750541839 cites W2096038417 @default.
• W2750541839 cites W2096283457 @default.
• W2750541839 cites W2097255042 @default.
• W2750541839 cites W2097995306 @default.
• W2750541839 cites W2098005365 @default.
• W2750541839 cites W2100039832 @default.
• W2750541839 cites W2100413206 @default.
• W2750541839 cites W2101477183 @default.
• W2750541839 cites W2101653483 @default.
• W2750541839 cites W2104347254 @default.
• W2750541839 cites W2105396178 @default.
• W2750541839 cites W2110930460 @default.
• W2750541839 cites W2111225997 @default.
• W2750541839 cites W2112121482 @default.
• W2750541839 cites W2112601576 @default.
• W2750541839 cites W2113960129 @default.
• W2750541839 cites W2114505219 @default.
• W2750541839 cites W2115964409 @default.
• W2750541839 cites W2116309119 @default.
• W2750541839 cites W2116839451 @default.
• W2750541839 cites W2117443086 @default.
• W2750541839 cites W2118471749 @default.
• W2750541839 cites W2118528246 @default.
• W2750541839 cites W2118902000 @default.
• W2750541839 cites W2120742047 @default.
• W2750541839 cites W2122835511 @default.
• W2750541839 cites W2123363005 @default.
• W2750541839 cites W2125885282 @default.
• W2750541839 cites W2127497577 @default.
• W2750541839 cites W2128362832 @default.

• next